Senstend

RSS

lidocaine / prilocaine

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Senstend has been withdrawn at the request of the marketing-authorisation holder.

This EPAR was last updated on 05/07/2022

Authorisation details

Product details
Name
Senstend
Agency product number
EMEA/H/C/005298
Active substance
  • lidocaine
  • prilocaine
International non-proprietary name (INN) or common name
  • lidocaine
  • prilocaine
Therapeutic area (MeSH)
Premature Ejaculation
Anatomical therapeutic chemical (ATC) code
N01BB20
Publication details
Marketing-authorisation holder
Plethora Pharma Solutions Limited
Date of issue of marketing authorisation valid throughout the European Union
14/11/2019
Contact address

32 Merrion Street
Upper Dublin 2
Ireland

Product information

14/11/2019 Senstend - EMEA/H/C/005298 -

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Anesthetics

Therapeutic indication

Senstend is indicated for the treatment of primary premature ejaculation in adult men.

Assessment history

How useful was this page?

Add your rating